Gantenerumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Gantenerumab
Accession Number
DB12034
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Gantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
4DF060P933
CAS number
1043556-46-2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Gantenerumab.
AbituzumabThe risk or severity of adverse effects can be increased when Gantenerumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Gantenerumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Gantenerumab.
AducanumabThe risk or severity of adverse effects can be increased when Gantenerumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Gantenerumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gantenerumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Gantenerumab.
AmatuximabThe risk or severity of adverse effects can be increased when Gantenerumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Gantenerumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911273
Wikipedia
Gantenerumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedOtherHealthy Participants1
1CompletedTreatmentAlzheimer's Disease (AD)2
1CompletedTreatmentHealthy Volunteers3
2, 3Active Not RecruitingTreatmentAlzheimers Disease / Alzheimers Disease, Familial / Dementias1
3Active Not RecruitingTreatmentAlzheimer's Disease (AD)2
3RecruitingTreatmentAlzheimer's Disease (AD)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:13 / Updated on November 02, 2018 07:19